Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry

Core Viewpoint - Ping An Biomedical Co., Ltd has entered into a non-binding investment memorandum with Future Biotechnology Group, involving an initial cash investment of US$30 million and potential future acquisitions totaling US$60 million, contingent on performance targets over a three-year evaluation period [1][2][6]. Investment Details - The initial investment is set at US$30 million in cash, with subsequent acquisitions amounting to US$60 million, which will be settled in cash and share issuances [2]. - The performance targets for the target company are as follows: - For 2026: Achieve audited revenue of no less than RMB 750 million [2][3]. - For 2027: Achieve audited revenue of no less than RMB 1.3 billion [3]. - For 2028: Achieve audited revenue of no less than RMB 2.3 billion [3]. - The consideration shares will be held in escrow and released based on the achievement of these performance targets, with adjustments made if targets are not met [4]. Company Overview - Future Biotechnology Group focuses on the biopharmaceutical sector, including R&D, genetic testing, medical devices, and pharmaceutical sales, while integrating AI into its operations to enhance efficiency [5]. - Ping An Biomedical's strategic investment aligns with its long-term goal of leveraging technology to empower healthcare, aiming to enhance competitiveness in the biopharmaceutical industry through collaboration with Future Biotechnology Group [6][7]. Industry Context - The biopharmaceutical industry is transitioning towards high-quality development, with a focus on industrial integration and clear technological pathways, which is expected to unlock long-term growth potential [7].